Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists

Annals of Pharmacotherapy

Volumn 33, Issue 4, 1999, Pages 480-488

  Dixon, Domeeka A ^a   Fenix, Lori A ^b   Kim, Denise M ^b   Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY   (United States)

^b NONE

Author keywords

Adenosine receptors; Antipsychotics; Dopamine D2 receptors; Schizophrenia

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT;

DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA;

ADENOSINE; ANIMALS; CAFFEINE; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; MUTATION; NEUROTRANSMITTER AGENTS; RECEPTORS, DOPAMINE D2; RECEPTORS, PURINERGIC P1; SCHIZOPHRENIA;

EID: 0032931515     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18215     Document Type: Review

References (94)

1. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52.
2. Potter WZ, Hollister LE. Antipsychotic agents & Iithium. In: Katzung BG, ed. Basic & clinical pharmacology. 7th ed. Stamford, CT: Appleton and Lange, 1998:464-82.
3. Crismon ML, Dorson PG. Schizophrenia. In: Dipiro JD, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy, a pathological approach. 3rd ed. Stamford, CT: Appleton and Lange, 1997: 1367-9.
4. Schizophrenia and other psychotic disorders. In: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:273-315.
5. Gottesman II. Schizophrenia genesis: the origins of madness. New York: WH Freeman and Co., 1991:1-9.
6. Jeste DV, del Carmen R, Lohr JB, Wyatt RJ. Did schizophrenia exist before the eighteenth century? Comp Psychiatry 1985;26:493-503.
7. Hare E. Schizophrenia as a recent disease. Br J Psychiatry 1988;153: 521-31.
8. Bark NM. On the history of schizophrenia: evidence of its existence before 1800. N Y State J Med 1988;88:374-83.
9. Cooper J, Sartorius N. Cultural and temporal variation in schizophrenia: a speculation on the importance of industrialization. Br J Psychiatry 1977;130:50-5.
10. Hare E. Was insanity on the increase? The fifty-sixth Maudsley Lecture. Br J Psychiatry 1983;142:439-55.
11. Bleuler E. Die prognose der dementia praecox (schizophreniegruppe). Allgemeine Z fur Psychiatr 1908;65:436-64.
12. Torrey EF, Bowler AE, Taylor EH, Gottesman II. Schizophrenia and manic-depressive disorder. New York: Basic Books, 1994:86-9.
13. Hyde TM, Casanova MF, Kleinman JE, Weinberger DR. Neuroanatomical and neurochemical pathology in schizophrenia. In: Tasman A, Goldfinger SM, eds. Review of psychiatry. Vol 10. Washington, DC: American Psychiatric Association Press, 1991:7-23.
14. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995;8:131-45.
15. Fernandez A, Hewicker M, Trautwein G, Pohlenz J, Liess B. Viral antigen distribution in the central nervous system of cattle persistently infected with bovine viral diarrhea virus. Vet Pathol 1989;26:26-32.
16. Nieuwenhuys R. Chemoarchitecture of the brain. Berlin: Springer-Verlag, 1985:14-9.
17. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44:660-9.
18. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology 1995;34.393-403.
19. 2a. Naunyn Schmiedebergs Arch Pharmacol 1996;353:261-71.
20. 2 receptors via intramembrane receptor-receptor interactions: relevance for Parkinson's disease and schizophrenia. Neurochem Int 1992; 20(suppl):215S-24S.
21. Ferré S. Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia. Psychopharmacology 1997; 133:107-20.
22. Watson S, Arkinstall S. The G-protein linked receptor factsbook. London: Academic Press, 1994:19-31.
23. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995;35:581-606.
24. 3H] CGS 21680. Eur J Pharmacol 1989;168.243-6.
25. 3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. J Neurochem 1990;55:1763-71.
26. James S, Xuereb JH, Askalan R, Richardson PJ. Adenosine receptors in post-mortem human brain. Br J Pharmacol 1992;105:238-44.
27. 2 receptors in the rat hippocampus. Brain Res 1994;649:208-16.
28. 1 adenosine receptor from rat brain. Mol Pharmacol 1991;40:1-7.
29. 2 dopamine receptors in rat striatum. Mol Brain Res 1992;14:186-95.
30. 2 receptor with psychological constitutive activity. Biochem Biophys Res Commun 1990;173:1169-78.
31. Zhou Q-Y, Li C, Olah ME, Johnson RA, Stiles GL, Civelli O. Molecular cloning and characterization of an adenosine receptor the A3 adenosine receptor. Proc Nad Acad Sci U S A 1992;89:7432-6.
32. Schwabe U, Fein T, Lorenzen A. Pharmacological properties of adenosine receptors and adenosine binding proteins. Drug Dev Res 1993;28: 220-5.
33. 2a receptor expression in striatal neurons: implications for basal ganglia pathophysiology. Drug Dev Res 1993;28:381-5.
34. Sebastião AM, Stone TW, Ribeiro JA. The inhibitory adenosine receptor at the neuromuscular junction and hippocampus of the rat: antagonism by 1,3,8-substituted xanthines. Br J Pharmacol 1990;101:453-9.
35. 2 adenosine receptors in the rat hippocampus. Neurosci Letts 1992;138:41-4.
36. 2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat NeuroReport 1995;6:1583-8.
37. 2 receptors. Eur J Pharmacol 1992; 227:317-24.
38. 2-like adenosine receptor on cerebral cortical neurons. J Pharmacol Exp Ther 1982;34:453-4.
39. Stone TW. Purine receptors involved in the depression of neuronal firing in cerebral cortex. Brain Res 1982;248:367-70.
40. 2 agonist, CGS 21680, is a potent depressant of cerebral cortical neuronal activity. Brain Res 1990;509:328-30.
41. Lin Y, Phillis JW. Characterization of the depression of rat cerebral cortical neurons by selective adenosine agonists. Brain Res 1991;540:307-10.
42. 2 receptor-mediated excitatory actions on the nervous system. Prog in Neurobiol 1996;48:167-89.
43. 2a purine receptors regulate striatal acetylcholine release. J Neurochem 1990;55:31-8.
44. 2 adenosine receptors modulate acetylcholine release from brain slices. Eur J Pharmacol 1984;97:341-2.
45. 2 adenosine receptors' involvement in controlling purine and acetylcholine release from rat hippocampal slices. Nucleos Nucleot 1991;10:1237-8.
46. 2a receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction. Eur J Pharmacol 1994;271:349-55.
47. Kirkpatrick KA, Richardson PJ. Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes. Br J Pharmacol 1993;110:949-54.
48. 2a receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci Letts 1995;196:41-4.
49. 2A receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J Neurochem 1993;60:2334-7.
50. 2 receptor interaction in globus pallidus. Synapse 1996;22:132-8.
51. 3H]acetylcholine release. J Neurochem 1994;62: 960-6.
52. 2A receptor-mediated modulation of striatal GABA and acetylcholine release. Br J Pharmacol 1994;113:43-8.
53. 2 agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci Letts 1992;138:169-72.
54. Okada Y, Nishimura S, Miyamoto T. Excitatory effect of adenosine on neurotransmission in the slices of superior colliculus and hippocampus of guinea pig. Neurosci Letts 1992;120:205-8.
55. Gonçalves J, Queiroz G. Facilatory and inhibitory modulation of endogenous adenosine of noradrenaline release in the epididymal portion of the rat vas deferens. Nauyn-Schmied Arch Pharmacol 1993;348:367-71.
56. Koizumi S, Watano T, Nakazawa K, Inoue K. Potentiation by adenosine of ATP-evoked dopamine release via a pertussis-sensitive mechanism in rat phaeochromocytoma PC12 cells. Br J Pharmacol 1994;112:992-7.
57. Zetterström T, Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol 1990;180:137-43.
58. 2A receptors. Trends Pharmacol Sci 1996;17:364-72.
59. 2 receptors in the ventral striopallidal system: implications for the treatment of schizophrenia. Neurosci 1994;63:765-73.
60. Daly JW. Adenosine receptors: targets for future drugs. J Med Chem 1982;25:197-207.
61. 6-(2-2-Diphenylethyl)-adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. J Med Chem 1987;30:1709-11.
62. Mayo KM, Falkowski W, Jones CA. Caffeine: use and effects in long-stay psychiatric patients. Br J Psychiatry 1993;162:543-5.
63. Honigfeld G, Klett CJ. The nurses' observation scale for in-patient evaluation - a new scale for measuring improvement in chronic schizophrenia. J Clin Psychol 1965;21:65-71.
64. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982;141:518-23.
65. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
66. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
67. Koczapski A, Paredes J, Kogan C, Ledwidge B, Higenbottam J. Effects of caffeine on behavior of schizophrenic inpatients. Schizophr Bull 1989;15:339-44.
68. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Homme: D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 1990;28:35-40.
69. Bunney WE, Hamberg DA. Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 1963;9:280-94.
70. Mathew RJ, Wilson WH, Tant S. Caffeine-induced cerebral blood flow changes in schizophrenia. Eur Arch Psychiatry Neurol Sci 1986;235: 206-9.
71. Dalby JT, Williams R. Caffeine use by psychiatric patients. Ir J Psychol Med 1989;6:103-5.
72. Clementz GL, Dailey JW. Psychotropic effects of caffeine. Am Fam Physician 1988;37:167-72.
73. Gilliland K, Bullock W. Caffeine: a potential drug of abuse. Adv Alcohol Subs Abuse 1983-84;3:53-73.
74. Sawyer DA, Julia HL, Turin AC. Caffeine and human behavior: arousal, anxiety, and performance effects. J Behav Med 1982;5:415-39.
75. Mackay DC, Rollins JW. Caffeine and caffeinism. J R Nav Med Serv 1989;75:65-7.
76. Victor BS, Lubetsky M, Greden JF. Somatic manifestations of caffeinism. J Clin Psychiatry 1981;42:185-8.
77. Greden JF, Fontaine P, Lubetsky M, Chamberlin K. Anxiety and depression associated with caffeinism among psychiatric inpatients. Am J Psychiatry 1978;135:963-6.
78. Rapoport JL, Elkins R, Neims A, Zahn T, Berg CJ. Behavioral and autonomic effects of caffeine in normal boys. Dev Pharmacol Ther 1981;3: 74-82.
79. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldbert R, Borrow J, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995;92: 7612-6.
80. Coon H, Holik J, Hoff M, Reimherr F, Wender P, Myles-Worsley M, et al. Analysis of chromosome 22 markers in nine schizophrenia pedigrees. Am J Med Genet 1994;54:72-9.
81. Pulver AE, Karayiorgou M, Wolyniec PS, Lasseter VK, Kasch L, Nestadt G, et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: part 1. Am J Med Genet 1994;54:36-43.
82. Schwab SG, Lerer B, Albus M, Maier W, Hallmayer J, Fimmers R, et al. Potential linkage for schizophrenia on chromosome 22q12-13: a replication study. Am J Med Genet 1995;60:436-43.
83. Vallada HP, Gill M, Sham P, Lim LCC, Nanko S, Asherson P, et al. Linkage studies on chromosome 22 in familial schizophrenia. Am J Med Genet 1995;60:139-46.
84. 2a receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum Genet 1997;99:326-8.
85. Kruglyak L, Lander E. High resolution genetic mapping of complex traits. Am J Hum Genet 1995;56:1212-23.
86. 2aAR) gene: systematic mutation screening in patients with schizophrenia. J Neural Transm 1996;103: 1447-55.
87. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
88. Martin GE, Rossi DJ, Jarvis MF. Adenosine agonists reduce conditioned avoidance responding in the rat. Pharmacol Biochem Behav 1993;45: 951-8.
89. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982;51:321-9.
90. Kuribara H, Tadokoro S. Correlation between antiavoidance activities and antipsychotic drugs in rats and daily clinical dose. Pharmacol Biochem Behav 1981;14:181-92.
91. 2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996;295:147-54.
92. 1 receptors. NeuroReport 1994;6:73-6.
93. 2 receptors in the neostriatum. Psychopharmacol Bull 1994;116:279-84.
94. 2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem 1995;65: 2057-64.